BR112023016903A2 - Formulação de suspensão aquosa para formação de aerossol, nebulizador, e, aerossol - Google Patents
Formulação de suspensão aquosa para formação de aerossol, nebulizador, e, aerossolInfo
- Publication number
- BR112023016903A2 BR112023016903A2 BR112023016903A BR112023016903A BR112023016903A2 BR 112023016903 A2 BR112023016903 A2 BR 112023016903A2 BR 112023016903 A BR112023016903 A BR 112023016903A BR 112023016903 A BR112023016903 A BR 112023016903A BR 112023016903 A2 BR112023016903 A2 BR 112023016903A2
- Authority
- BR
- Brazil
- Prior art keywords
- aerosol
- suspension formulation
- aqueous suspension
- nebulizer
- formation
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title abstract 6
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 239000007900 aqueous suspension Substances 0.000 title abstract 3
- 230000015572 biosynthetic process Effects 0.000 title abstract 3
- 239000006199 nebulizer Substances 0.000 title abstract 2
- -1 poly(propylene oxide) Polymers 0.000 abstract 4
- 150000002632 lipids Chemical class 0.000 abstract 3
- 239000008365 aqueous carrier Substances 0.000 abstract 2
- 239000002105 nanoparticle Substances 0.000 abstract 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 229920001451 polypropylene glycol Polymers 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 229920000428 triblock copolymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21159455 | 2021-02-26 | ||
| PCT/EP2022/054796 WO2022180213A1 (en) | 2021-02-26 | 2022-02-25 | Formulations for aerosol formation and aerosols for the delivery of nucleic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023016903A2 true BR112023016903A2 (pt) | 2023-10-10 |
Family
ID=74797735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023016903A BR112023016903A2 (pt) | 2021-02-26 | 2022-02-25 | Formulação de suspensão aquosa para formação de aerossol, nebulizador, e, aerossol |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240156729A1 (https=) |
| EP (1) | EP4297722A1 (https=) |
| JP (1) | JP2024507394A (https=) |
| KR (1) | KR20230152014A (https=) |
| CN (1) | CN116887812A (https=) |
| AU (1) | AU2022226409A1 (https=) |
| BR (1) | BR112023016903A2 (https=) |
| CA (1) | CA3209032A1 (https=) |
| IL (1) | IL305353A (https=) |
| MX (1) | MX2023009757A (https=) |
| WO (1) | WO2022180213A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024042236A1 (en) * | 2022-08-26 | 2024-02-29 | Ethris Gmbh | Stable lipid or lipidoid nanoparticle suspensions |
| EP4327829A1 (en) * | 2022-08-26 | 2024-02-28 | Ethris GmbH | Stabilization of lipid or lipidoid nanoparticle suspensions |
| CN115417778B (zh) * | 2022-11-01 | 2023-06-20 | 北京华芢生物技术有限公司 | 可离子化的阳离子脂c5及由其组成的纳米脂质体颗粒 |
| CN115708818B (zh) * | 2022-11-03 | 2023-07-18 | 荣灿生物医药技术(上海)有限公司 | 一种用于雾化吸入脂质纳米粒的通用型处方 |
| CN115433099B (zh) * | 2022-11-03 | 2023-06-16 | 北京华芢生物技术有限公司 | 可离子化的阳离子脂c6及由其组成的纳米脂质体颗粒 |
| CN120752027A (zh) * | 2023-03-24 | 2025-10-03 | 星锐医药(苏州)有限公司 | 编码治疗性多肽的核酸及包含所述核酸的脂质纳米颗粒组合物 |
| CN121712488A (zh) * | 2023-08-14 | 2026-03-20 | 埃泽瑞斯公司 | 非全身性mRNA施用 |
| CN121729225A (zh) * | 2023-08-25 | 2026-03-24 | 埃泽瑞斯公司 | 具有增强药物应用的特定表面活性剂性质的稳定脂质和类脂质纳米颗粒制剂 |
| WO2025088192A1 (en) | 2023-10-27 | 2025-05-01 | Xl-Protein Gmbh | Methods for the coupling of di(alkyl)amines to polypeptides |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6017700A (en) | 1995-08-04 | 2000-01-25 | Bayer Corporation | Cationic oligonucleotides, and related methods of synthesis and use |
| CA2294334A1 (en) * | 1997-06-13 | 1998-12-17 | Adi Eisenberg | Compositions for delivery of biological agents and methods for the preparation thereof |
| DE19834683A1 (de) | 1997-08-13 | 1999-04-01 | Biontex Lab Gmbh | Neue Lipopolyamine, deren Darstellung und Anwendung |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| WO2006138380A2 (en) | 2005-06-15 | 2006-12-28 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
| NZ569138A (en) | 2005-12-15 | 2012-06-29 | Centre Nat Rech Scient | Cationic oligonucleotides automated methods for preparing same and their uses |
| US7897737B2 (en) | 2006-12-05 | 2011-03-01 | Lasergen, Inc. | 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing |
| CA2721183C (en) | 2008-04-11 | 2019-07-16 | Alnylam Pharmaceuticals, Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| EP3269395A1 (en) | 2008-11-07 | 2018-01-17 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| KR101766408B1 (ko) | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| CA2769670C (en) | 2009-07-31 | 2018-10-02 | Ethris Gmbh | Rna with a combination of unmodified and modified nucleotides for protein expression |
| US8648017B2 (en) * | 2009-11-04 | 2014-02-11 | Diamir, Llc | Methods of using small RNA from bodily fluids for diagnosis and monitoring of neurodegenerative diseases |
| US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| EP2817287B1 (en) | 2012-02-24 | 2018-10-03 | Arbutus Biopharma Corporation | Trialkyl cationic lipids and methods of use thereof |
| WO2014028487A1 (en) | 2012-08-13 | 2014-02-20 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
| US12064484B2 (en) | 2013-06-28 | 2024-08-20 | Ethris Gmbh | Compositions for introducing RNA into cells |
| JP2017500865A (ja) | 2013-12-19 | 2017-01-12 | ノバルティス アーゲー | レプチンｍＲＮＡの組成物および製剤 |
| EP3034539A1 (en) | 2014-12-19 | 2016-06-22 | Ethris GmbH | Compositions for introducing nucleic acid into cells |
-
2022
- 2022-02-25 IL IL305353A patent/IL305353A/en unknown
- 2022-02-25 EP EP22706337.7A patent/EP4297722A1/en active Pending
- 2022-02-25 MX MX2023009757A patent/MX2023009757A/es unknown
- 2022-02-25 KR KR1020237029355A patent/KR20230152014A/ko active Pending
- 2022-02-25 WO PCT/EP2022/054796 patent/WO2022180213A1/en not_active Ceased
- 2022-02-25 AU AU2022226409A patent/AU2022226409A1/en active Pending
- 2022-02-25 US US18/277,965 patent/US20240156729A1/en active Pending
- 2022-02-25 BR BR112023016903A patent/BR112023016903A2/pt unknown
- 2022-02-25 CN CN202280017480.5A patent/CN116887812A/zh active Pending
- 2022-02-25 CA CA3209032A patent/CA3209032A1/en active Pending
- 2022-02-25 JP JP2023551966A patent/JP2024507394A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116887812A (zh) | 2023-10-13 |
| MX2023009757A (es) | 2023-09-04 |
| CA3209032A1 (en) | 2022-09-01 |
| WO2022180213A1 (en) | 2022-09-01 |
| IL305353A (en) | 2023-10-01 |
| US20240156729A1 (en) | 2024-05-16 |
| KR20230152014A (ko) | 2023-11-02 |
| JP2024507394A (ja) | 2024-02-19 |
| EP4297722A1 (en) | 2024-01-03 |
| AU2022226409A1 (en) | 2023-08-10 |
| AU2022226409A9 (en) | 2024-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023016903A2 (pt) | Formulação de suspensão aquosa para formação de aerossol, nebulizador, e, aerossol | |
| WO2022216787A3 (en) | Lipid nanoparticles and methods of use | |
| WO2022120388A3 (en) | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof | |
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| EP4656242A3 (en) | Compositions and methods of treating muscle dystrophy | |
| EP4613741A3 (en) | Lipid nanoparticles for oligonucleotide delivery | |
| BR112018010635A2 (pt) | linhagens celulares estáveis para a produção retroviral | |
| MX2022013612A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas. | |
| JO3430B1 (ar) | مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها | |
| PH12017502236A1 (en) | 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as jak inhibitors | |
| AU2017228405A8 (en) | Small molecule IRE1-alpha inhibitors | |
| BR112018009297A8 (pt) | composição de limpeza e desinfecção | |
| PH12012502334A1 (en) | Heteroaryl imidazolone derivatives as jak inhibitors | |
| MX2024005110A (es) | Nanoparticulas lipidicas para administracion de oligonucleotidos. | |
| NO20082269L (no) | Nye piperaziner som antimalariamidler | |
| AU2020231934A8 (en) | Compounds useful in HIV therapy | |
| BR112014014800A2 (pt) | composições de cuidado oral | |
| BR112014009199A2 (pt) | formulação, uso de uma formulação, e, processo para a produção de uma formulação | |
| AR059927A1 (es) | Metodos para la estabilizacion de composiciones inestables a la oxidacion y composiciones oftalmicas estabilizadas | |
| BR112021023282A2 (pt) | Composto, método para preparar um composto de fórmula química 1, e, composição farmacêutica | |
| JO3388B1 (ar) | تركيبة دوائية ثابتة للإعطاء عن طريق الفم تضم ليفوسيتيريزين أو ملح منه مقبول دوائياً، و منتولوكاست أو ملح منه مقبول دوائياً | |
| BR112018008506A2 (pt) | inibidores do fator xia | |
| BR112015022385A2 (pt) | droga para uma doença respiratória | |
| MX2024001055A (es) | Composiciones de vectores de acidos nucleicos. | |
| BR112018012043A2 (pt) | processo para a redução da transpiração |